cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

2020/01/29 by Daniel J. Brat, Kenneth Aldape, Howard Colman +18 · 540 citations
Medicine · Neuroscience · #Biology #Computational biology #Ecology #Epilepsy research and treatment #Gene #Genetics #Glioma Diagnosis and Treatment #Grading (engineering) #Medicine #Mutant #Neuroscience and Neuropharmacology Research

paper · doi:10.1007/s00401-020-02127-9

published in Acta Neuropathologica 139(3), 603-608 (Springer Science+Business Media)

openalex publication_date 2020/01/29 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05

Abstract

International audience

Citations

• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
• cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

Cited by

• Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas
• Recurrent oligodendroglioma with changed 1p/19q status
• Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma
• Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
• The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
• The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know
• cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas
• T2-FLAIR digital subtraction radiomics versus neuroradiologist visual assessment for differentiating IDH-mutant astrocytomas from other non-enhancing low-grade gliomas: An externally validated machine learning study
• Comparison of Fluorescence In Situ Hybridization, Next-Generation Sequencing, and DNA Methylation Microarray for Copy Number Variation Assessment in Gliomas
• EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
• Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. [europepmc]
• A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. [europepmc]
• Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. [europepmc]
• Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing. [europepmc]
• Cell senescence in neuropathology: A focus on neurodegeneration and tumours. [europepmc]
• IDH1 mutations induce organelle defects via dysregulated phospholipids. [europepmc]
• Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH -mutant glioblastoma. [europepmc]
• Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. [europepmc]
• Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. [europepmc]
• The immune landscape of common CNS malignancies: implications for immunotherapy. [europepmc]
• The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. [europepmc]
• Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. [europepmc]
• Prognostic and Predictive Biomarkers in Gliomas. [europepmc]
• Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging. [europepmc]
• Hypoxia: The Cornerstone of Glioblastoma. [europepmc]
• Major Features of the 2021 WHO Classification of CNS Tumors. [europepmc]
• The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know. [europepmc]
• Survival Outcomes and Prognostic Factors in Glioblastoma. [europepmc]
• The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know-a minireview. [europepmc]
• The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics. [europepmc]
• Cellular senescence in cancer: clinical detection and prognostic implications. [europepmc]
• Signaling pathways in brain tumors and therapeutic interventions. [europepmc]
• Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors. [europepmc]
• The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen. [europepmc]
• Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. [europepmc]

Related

• cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas
• cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
• cIMPACT ‐ NOW update 10: Recommendations for defining new types for central nervous system tumor classification
• A threshold for mitotic activity and post‐surgical residual volume defines distinct prognostic groups for astrocytoma IDH‐mutant
• The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know